---
title: "Thalys Medical Technology Group Corporation. (603716.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/603716.SH.md"
symbol: "603716.SH"
name: "Thalys Medical Technology Group Corporation."
industry: "Biotechnology"
datetime: "2026-05-20T08:13:38.347Z"
locales:
  - [en](https://longbridge.com/en/quote/603716.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/603716.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/603716.SH.md)
---

# Thalys Medical Technology Group Corporation. (603716.SH)

## Company Overview

Thalys Medical Technology Group Corporation provides medical integrated operation and management services in China. It offers automated immunofluorescence analyzer; coagulation reagent; COVID-19 test kit; line blot1 fully automated immunoblotting instrument; and flow products. The company also provides automated coagulation analyzer; automated immunoassay system; automated biochemical analysis system; automated chemiluminescence immunoassay system; and blood analyzer. The company was formerly known as Thalys Medical Technology Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | CN Market |
| Website | [www.thalys.net.cn](https://www.thalys.net.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: D (0.66)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 74 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -39.78% |  |
| Net Profit YoY | 7.16% |  |
| P/B Ratio | 4.67 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 4722897004.81 |  |
| Revenue | 973047807.44 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -21.63% | E |
| Profit Margin | -21.67% | D |
| Gross Margin | 25.16% | C |
| Revenue YoY | -39.78% | E |
| Net Profit YoY | 7.16% | C |
| Total Assets YoY | -23.42% | E |
| Net Assets YoY | 4.82% | C |
| Cash Flow Margin | 0.72% | D |
| OCF YoY | -39.78% | E |
| Turnover | 0.48 | C |
| Gearing Ratio | 43.29% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Thalys Medical Technology Group Corporation.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-39.78%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "7.16%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "4.67",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "4722897004.81",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "973047807.44",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-21.63%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-21.67%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "25.16%",
          "rating": "C"
        },
        {
          "name": "Revenue YoY",
          "value": "-39.78%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "7.16%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "-23.42%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "4.82%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "0.72%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-39.78%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.48",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "43.29%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -22.40 | 58/81 | - | - | - |
| PB | 4.67 | 56/81 | 6.38 | 4.67 | 4.19 |
| PS (TTM) | 4.85 | 20/81 | 4.19 | 3.72 | 3.36 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A |
| 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A |
| 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B |
| 04 | RemeGen (688331.SH) | A | A | C | C | B | B |
| 05 | InnoCare Pharma (688428.SH) | B | A | D | B | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/603716.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/603716.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/603716.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/603716.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**